Game On: Topokine Initiates Late-Stage Trial of XAF5 Ointment for Reining in Undereye Bags
Topokine Therapeutics initiated a Phase 2b/3 trial for XAF5 Ointment for the reduction of undereye bags.
Topokine Therapeutics initiated a Phase 2b/3 trial for XAF5 Ointment for the reduction of undereye bags.
The agreement allows Elevai to commercialize use of the proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost.
Apyx Medical Corp., the manufacturer of the proprietary Renuvion technology, announces that it has received U.S. FDA 510(k) clearance for the use of the Renuvion APR Handpiece for coagulation of subcutaneous soft tissues following liposuction.
Researchers from Florida Atlantic University have received a four-year, $1.2 million grant from the National Science Foundation to empower amputees to maximize their individual potential for controlling the full dexterity of artificial hands.
Advalight, which offers the ADVATx dermatology laser, announces that Beverly Hills, Calif.-based, board-certified plastic surgeon Daniel Barrett, MD, is now providing its non-ablative laser treatments.
Apyx Medical Corp.—developer of Helium Plasma Technology, which is marketed and sold as Renuvion® in the cosmetic surgery market—announces it has submitted a 510(k) premarket notification to the U.S. FDA.